ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1463	National Cancer Institute	Html	en	Renal Cell Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of renal cell cancer.	2-week washout period 0.566416 Transitional Cell Cancer 0.481465 treatment 0.601534 Patient Preference Study 0.474292 sunitinib treatment 0.529856 10-week treatment period 0.482517 VEGF receptors 0.467264 well-differentiated renal adenocarcinomas 0.509726 pazopanib arm 0.470964 sunitinib side effects 0.517044 true treatment break 0.474342 primary endpoint 0.499973 patients preferred pazopanib 0.531227 immediately surrounding tissue 0.462945 6-week treatment cycle 0.515867 trial 0.472067 Late tumor recurrence 0.47026 Pazopanib Versus Sunitinib 0.55357 cytoreductive nephrectomy extends 0.466923 High-dose IL-2 0.463042 patient treatment 0.463771 occasional selected patients 0.50375 overall survival 0.481487 rating scale 0.463587	toxic effects 0.499682 axitinib versus sorafenib 0.467683 sorafenib patients 0.470445 sunitinib 0.625595 renal cell cancer 0.570239 recurrent renal cell 0.504482 metastatic disease 0.476849 external-beam radiation therapy 0.463579 patients 0.74513 Metastatic Kidney Cancer 0.465785 initial cytoreductive nephrectomy 0.466065 median PFS time 0.4636 renal adenomas 0.481736 4-week treatment cycle 0.477666 renal cell carcinoma 0.969838 renal cell carcinoma. 0.553709 transitional cell carcinomas 0.485832 clear-cell renal cell 0.607225 renal cell cancers 0.532142 renal pelvis 0.520062 10-week treatment periods 0.476333 metastatic renal cell 0.598995 renal cell carcinomas 0.527788	CLICK HERE
1524	National Cancer Institute	Html	en	Endometrial Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of endometrial cancer.	cancer treatment 0.541916 Lymph node dissection 0.478324 metastatic endometrial cancer 0.510561 body 0.511838 PDQ cancer information 0.531329 clinical trial search 0.465384 uterus 0.585793 endometrial cancer spreads 0.509404 mTOR inhibitors 0.464666 clinical trials 0.736061 cancer information summary 0.508345 clinical trial 0.5843 Low-risk endometrial cancer 0.501844 breast cancer patients 0.483969 patients 0.494506 NCI PDQ cancer 0.479485 malignant tumor cells 0.467809 lymph nodes 0.52827 endometrial hyperplasia 0.468477 radiation therapy 0.605187 Treatment Editorial Board 0.469208 endometrial cancer 0.889926 radical hysterectomy 0.471844 treatment 0.622425 cancer prevention 0.463817	new cancer treatments 0.470535 NCI-supported cancer 0.463476 cancer cells 0.753566 Cancer Information Service 0.471559 specific cancer cells 0.479989 treatment clinical trials 0.48357 High-risk endometrial cancer 0.500552 endometrial tissue 0.464689 National Cancer Institute 0.508844 new treatment 0.504217 cervix 0.474629 external radiation therapy 0.482834 non-polyposis colon cancer 0.477796 tissue samples 0.463584 cancer research process 0.465542 cancer clinical trials 0.501833 stage 0.522219 Endometrial Cancer Treatment 0.516218 Recurrent endometrial cancer 0.629078 fallopian tubes 0.494755 cancer information summaries 0.469865 treatment options 0.466033 comprehensive cancer information 0.469896 internal radiation therapy 0.504839	CLICK HERE
1577	National Cancer Institute	Html	en	Retinoblastoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of retinoblastoma in children.	cancer treatment 0.489298 body 0.467706 type 0.422666 PDQ cancer information 0.456409 clinical trial search 0.418893 retinoblastoma 0.865388 retinoblastoma treatment centers 0.451209 systemic chemotherapy 0.574478 regular eye exams 0.443823 clinical trials 0.855386 recurrent intraocular retinoblastoma 0.415908 high-dose chemotherapy 0.465125 cancer information summary 0.42823 clinical trial 0.564195 patients 0.408556 eye 0.840016 radiation therapy 0.862799 optic nerve 0.459799 child 0.430789 heritable form 0.409154 treatment 0.773723 bilateral intraocular retinoblastoma 0.418197 heritable retinoblastoma 0.466245 Nonheritable retinoblastoma 0.41969 cancer cells 0.573196	extraocular retinoblastoma 0.479879 retinoblastoma cells 0.416299 Intravitreal chemotherapy 0.407999 treatment clinical trials 0.426091 RB1 gene 0.435629 National Cancer Institute 0.44282 spinal cord 0.437008 intraocular retinoblastoma 0.468181 effects cancer treatment 0.415229 new treatment 0.441768 artery infusion chemotherapy 0.538311 external-beam radiation therapy 0.642309 recurrent extraocular retinoblastoma 0.414269 ophthalmic artery infusion 0.504849 metastatic retinoblastoma 0.407008 trilateral retinoblastoma 0.466869 bone marrow 0.434989 cancer clinical trials 0.449674 cavitary retinoblastoma 0.436997 stem cell rescue 0.535096 tumor 0.495126 retinoblastoma spreads 0.40533 internal radiation therapy 0.438773 cancer 0.972687	CLICK HERE
1611	National Cancer Institute	Html	en	Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version	Serious, disabling, and life-threatening chronic health conditions adversely affect the health of aging childhood cancer survivors. Learn about the cardiovascular, cognitive, psychosocial, digestive, endocrine, immune, musculoskeletal, reproductive, and urinary late effects and subsequent neoplasms that contribute to a high burden of morbidity in childhood cancer survivors.	adult cancer survivors 0.344142 childhood leukemia survivors 0.307057 Childhood Cancer Guideline 0.302298 childhood cancer therapy 0.296791 long-term cancer survivors 0.295333 childhood cancer survivors 0.499567 Engl J Med 0.269755 Br J Cancer 0.261959 Cancer Survivor cohort 0.269169 Int J Cancer 0.266011 Ann Intern Med 0.263377 5-year survivors 0.295172 cancer survivors research 0.286942 Radiat Oncol Biol 0.277048 breast cancer surveillance 0.269328 adult survivors 0.315122 Hudson MM 0.309712 young adult cancer 0.340977 British Childhood Cancer 0.326521 Natl Cancer Inst 0.402086 survivor study cohort 0.273371 Clin Cancer Res 0.263669 Irradiated Childhood Cancer 0.298512 childhood cancer 0.912384 cancer survivor study 0.693286	et al. 0.431618 late effects 0.3275 long-term survivors 0.333244 cohort study 0.263432 Cancer Epidemiol Biomarkers 0.265429 pediatric cancer survivors 0.286679 PUBMED Abstract 0.35078 Pediatr Blood Cancer 0.447984 radiation-induced breast cancer 0.26406 breast cancer risk 0.280733 Abstract 0.467444 Clin Oncol 0.515912 breast cancer 0.391476 Oncol Biol Phys 0.278259 childhood cancer survivor 0.771953 Cancer Guideline Harmonization 0.260525 young cancer survivors 0.275759 childhood cancer registry 0.291062 long-term follow-up guidelines 0.273165 Cancer J Clin 0.270171 report 0.265432 childhood cancer treatment 0.287484 oncology group 0.32484 long-term childhood cancer 0.311378	CLICK HERE
1740	National Cancer Institute	Html	en	Hair Dyes and Cancer Risk	A fact sheet that reviews research about the possibility of a connection between personal hair dye use and cancer.	female breast cancer 0.364162 hair dye 0.94208 hair dye products 0.547022 hair dyes 0.824788 Kupelnick B. Personal 0.356107 Modern hair dyes 0.445893 C. Personal hair 0.381701 case-control study 0.408793 bladder cancer 0.729938 consumer exposure study 0.34979 permanent hair dye 0.484417 increased risk 0.395633 case-control studies 0.347772 bladder cancer risk 0.47239 Montes-Martinez A. Personal 0.354703 IARC Working Group 0.350056 permanent hair dyes 0.502056 MR. Bladder cancer 0.389163 American Journal 0.365295 temporary hair dyes 0.442658 hair coloring products 0.388447 currently marketed products 0.354822 leukemia/small lymphocytic lymphoma 0.349931 colorless dye 0.417079 A. Bladder cancer 0.391043	Cancer Epidemiology Biomarkers 0.364493 International Journal 0.379963 public health impact 0.349406 black permanent dyes 0.401612 color dyes 0.375257 Personal permanent hair 0.383955 United States 0.383182 adult acute leukemia 0.391088 non-Hodgkin lymphoma 0.350907 conflicting results 0.412706 bladder cancer study 0.39321 earlier hair dyes 0.42871 personal hair dye 0.756765 studies 0.389653 bladder-cancer risk 0.359564 public health 0.351318 dark-colored dyes 0.399225 follicular lymphoma 0.348182 recent dye formulations 0.42394 aromatic amines 0.360034 hair dye formulations 0.474224 specific NHL subtypes 0.351636 hair dye users 0.497516 et al 0.482744	CLICK HERE
1876	National Cancer Institute	Html	es	Tratamiento de los tumores de ovario de bajo potencial maligno (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores de ovario de bajo potencial maligno.	estadio lV 0.336073 Obstet Gynecol 0.332535 Are borderline tumors 0.338893 Radium Hospital from 0.383601 low malignant 0.947577 Norwegian Radium Hospital 0.384329 Abeler VM 0.345874 long-term follow-up 0.429878 serous tumors 0.367951 Leake JF 0.387334 ovary treated 0.34981 Instituto Nacional 0.327748 malignant potential with 0.326796 Rosenshein NB 0.34897 Federation Internationale 0.32197 University Medical Center 0.328522 Kaern J 0.406737 endometrioid tumors 0.337973 Gynecologic Oncology Group 0.336842 Gynecol Oncol 0.811816 lavados peritoneales 0.350751 New York University 0.326742 Icb Tumor 0.324006 retrospective study 0.363127 cellular dna content 0.335807	Bell DA 0.339598 patients with borderline 0.366646 malignant potential treated 0.323909 borderline tumors with 0.347412 borderline tumors 0.629125 clinicopathologic features 0.350407 tumores aneuploides 0.321014 estadio ia 0.33807 Oncology Group study 0.347633 with borderline tumors 0.383311 IIIa Tumor 0.323737 Kurman RJ 0.323851 PDQ Tratamiento 0.323544 Gynecol Pathol 0.337197 New York 0.330732 York University Medical 0.327419 Currie JL 0.350075 Ovarian epithelial tumors 0.334479 Clin Oncol 0.355682 Tropé CG 0.345953 Lage JM 0.321478 tumor residual macroscópico 0.331365 Gynecol Cancer 0.321099 serous borderline tumors 0.4289	CLICK HERE
3454	National Cancer Institute	Html	es	Grados de comprobación científica de los estudios de terapias integrales, alternativas y complementarias en seres humanos con cáncer (PDQ®)–Versión para profesionales de salud	Información acerca de cómo evaluar la solidez de los datos probatorios obtenidos de los estudios de investigación sobre terapias integrales, alternativas y complementarias en seres humanos con cáncer.	Visuals Online 0.6561 grupo control 0.658003 Physician Data Query 0.707803 distintos tipos 0.676327 mejores casos— 0.670195 valoración indirectos 0.860816 tratamiento versus muerte 0.748944	National Cancer Institute 0.697449 personas ayuda 0.673043 siguientes riesgos 0.659857 mejores casos 0.807578 versus muerte 0.798627 Instituto Nacional 0.960893	CLICK HERE
3551	National Cancer Institute	Html	en	Cancer Statistics	Basic information about cancer statistics in the U.S. and how they are used to understand the impact of cancer on society and to develop strategies that address the challenges that cancer poses.	cancer statistics 0.699332 major impact 0.569457 new screening test 0.610486 United States 0.848591 Asian/Pacific Islander women 0.623563 cancer death rate 0.734611 cancer deaths 0.662668 thyroid cancer 0.618391 SEER program website 0.613262 renal pelvis cancer 0.675159 population-based cancer registries 0.661094 African American men 0.620993 number 0.579668 new cancer cases 0.74726 American Cancer Society 0.655347 pancreatic cancer 0.619919 bladder cancer 0.619451 cancer-related deaths 0.575865 average age 0.568157 individual cancer types 0.652597 North American Association 0.605716 racial/ethnic group 0.570832 cancer care 0.615369 cancer diagnosis 0.664799	breast cancer 0.617639 rectum cancer 0.622513 large groups 0.569141 risk factor 0.614571 U.S. population 0.610565 people 0.571698 statistical trends 0.613522 age-adjusted mortality 0.572947 prostate cancer 0.619132 bronchus cancer 0.62075 Central Cancer Registries 0.654709 cancer survivors 0.603772 cancer mortality 0.652323 policy makers 0.566593 Understanding Cancer Prognosis 0.676403 endometrial cancer 0.620993 cancer 0.951216 new cases 0.679157 cancer incidence 0.694185 cancer death rates 0.665983 SEER Cancer Statistics 0.665479 overall cancer death 0.735155 cancer rates 0.609223	CLICK HERE
3678	National Cancer Institute	Html	en	NCI Outstanding Investigator Award Recipients	Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research.	Professor 0.818386 cancer cell fate 0.872486 tumor interstitial fluid 0.811256 Institution 0.848074 brain cancer stem 0.81847 Salk Institute Cancer 0.836669 cancer therapy 0.800257 ccRCC tumor metabolism 0.813028 cancer stem cell 0.87789 Harvard Medical School 0.902146 Institute Cancer Center 0.918217 Mount Sinai Cancer 0.82427 interactive research areas 0.831532 new therapeutic targets 0.831101 Tisch Cancer Institute 0.836924 tumor suppressor functions 0.808451 Cell Biology Laboratory 0.802354 clinical cancer research 0.915827 Hopkins University School 0.800509 Medical Research 0.805386 molecular mechanisms 0.847735 human cancer metabolism 0.844789 kidney cancer subtype 0.813888 Cancer Research Program 0.87416 mouse models 0.817082	leukemia cell metabolism 0.821118 Cancer Research Center 0.897578 cancer cell metabolism 0.867114 cancer cells 0.87218 Stem Cell Biology 0.799482 distinct cell types 0.801724 Anderson Cancer Center 0.828569 cancer research 0.977431 Adolphus Pfeiffer Professor 0.801659 HGG cancer cell 0.848375 tumor suppressor gene 0.80279 Center Research Institute 0.861555 Title 0.835958 Cancer Society Research 0.870208 Stem Cell Research 0.847258 Cell Biology 0.815108 tumor microenvironment signals 0.812505 Cancer Imaging Research 0.895426 Cell Biology Department 0.805035 acute lymphoblastic leukemia 0.839865 Bakar Distinguished Professor 0.809836 Wistar Institute Cancer 0.864712 M. Temin Professor 0.801808 tumor microenvironment 0.889603	CLICK HERE
16845	National Cancer Institute	Html	en	Masimo Corporation — Mechanical Drugs: Harnessing Cancer Aggressiveness to Overcome Its Resistance	Developing a new therapeutic approach to triple negative breast cancer (TNBC) which is based on intracellular mechanical impact generated by plasmonic nanobubbles.	synergy 0.336432 gold nanoparticles 0.550066 liposome-encapsulated drugs 0.504619 M.D. 0.377619 intracellular gold nanoparticle 0.766413 project team 0.493532 chemotherapy 0.340382 bubble generation threshold 0.657269 short laser pulse 0.734768 Ph.D. 0.365843 TNBC 0.333035 higher selectivity 0.504113 goal 0.33328 accumulation 0.342776 absorption 0.340473 negative breast cancer 0.692185 nanomaterials 0.340596 Co-Investigators 0.334002 plasmonic nanobubbles 0.543572 Principal Investigators 0.516256 Resistance 0.336765 radiotherapy 0.347319 Masimo Corporation 0.532528 Mechanical Drugs 0.555482 EGFR-expressing cancer cells 0.691288	Vladimir Torchilin 0.519417 optical energy 0.499453 Ph.D 0.376534 larger gold clusters 0.685801 mechanical impact 0.858201 modalities 0.337622 radiation oncology 0.496973 Mien-Chie Hung 0.526833 nanobubble-disrupted liposomes 0.520675 Cancer Aggressiveness 0.580782 normal cells 0.511798 laser pulse 0.92023 Gillenwater 0.333958 Jack Phan 0.537018 host cell 0.497762 non-stationary vapor bubbles 0.750751 gold nanoclusters 0.536739 new therapeutic approach 0.68193 Nie 0.367583 Dmitri Lapotko 0.533767 molecular / cell 0.487681 low-energy laser pulse 0.711917 intracellular mechanical impact 0.751573 cancer biology 0.50282	CLICK HERE